http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Jang, Albert Youngwoo,O Brien, Connor,Chung, Wook-Jin,Oh, Pyung Chun,Yu, Jongwook,Lee, Kyounghoon,Kang, Woong Chol,Moon, Jeonggeun UNKNOWN 2018 CIRCULATION JOURNAL Vol.82 No.6
<P>Conclusions: Based on this retrospective analysis, the routine use of IUC may increase length of stay and UTI complications in AHF patients without reducing the risk for major cardiovascular and cerebrovascular events or 30-day rehospitalization rate.</P>
Epidemiology of PAH in Korea: An Analysis of the National Health Insurance Data, 2002–2018
Albert Youngwoo Jang,Hyeok-Hee Lee,Hokyou Lee,Hyeon Chang Kim,Wook-Jin Chung 대한심장학회 2023 Korean Circulation Journal Vol.53 No.5
Background and Objectives: Pulmonary arterial hypertension (PAH) is a rare but fatal disease. Recent advances in PAH-specific drugs have improved its outcomes, although the healthcare burden of novel therapeutics may lead to a discrepancy in outcomes between developing and developed countries. We analyzed how the epidemiology and clinical features of PAH has changed through the rapidly advancing healthcare infrastructure in South Korea. Methods: PAH was defined according to a newly devised 3-component algorithm. Using a nationwide health insurance claims database, we delineated annual trends in the prevalence, incidence, medication prescription pattern, and 5-year survival of PAH in Korea. Cumulative survival and potential predictors of mortality were also assessed among 2,151 incident PAH cases. Results: Between 2002 or 2004 and 2018, the prevalence and incidence of PAH increased 75-fold (0.4 to 29.9 per million people) and 12-fold (0.5 to 6.3 per million person-years), respectively. The proportion of patients on combination PAH-specific drug therapy has also steadily increased up to 29.0% in 2018. Among 2,151 incident PAH cases (median [interquartile range] age, 50 [37–62] years; 67.2% female), the 5-year survival rate and median survival duration were 71.8% and 13.1 years, respectively. Independent predictors of mortality were age, sex, etiology of PAH, diabetes, dyslipidemia, and chronic kidney disease. Conclusions: This nationwide study delineated that the prevalence and incidence of PAH have grown rapidly in Korea since the early 2000s. The use of combination therapy has also increased, and the 5-year survival rate of PAH in Korea was similar to those in western countries.
Jina Yeo,신나미,안경진,서미령,Albert Youngwoo Jang,김민수,정욱진 대한고혈압학회 2022 Clinical Hypertension Vol.28 No.-
Pulmonary arterial hypertension (PAH) is the second most common lung complication in antiphospholipid syndrome (APS) patients. However, the concurrent development of APS-related nonthrombotic PAH is rarely reported. Lack of awareness for group 1 PAH in APS patient may contribute to underdiagnosis of this condition. Herein, we reviewed the case of a 56-year-old female who was diagnosed with PAH related to APS that mimicked chronic thromboembolic pulmonary hypertension (CTEPH). It is crucial to be aware of the possibility of a group 1 PAH diagnosis, even though patients have already been diagnosed with CTEPH. Furthermore, a multidisciplinary approach and serial follow-up right heart catheterization with echocardiography are important to make a timely diagnosis and provide optimal treatment for APS-related PAH in patients with CTEPH-like clinical features.
Stem Cell and Exosome Therapy in Pulmonary Hypertension
Seyeon Oh,Ji-Hye Jung,Kyung-Jin Ahn,Albert Youngwoo Jang,Kyunghee Byun,Phillip C. Yang,Wook-Jin Chung 대한심장학회 2022 Korean Circulation Journal Vol.52 No.2
Pulmonary hypertension is a rare and progressive illness with a devastating prognosis. Promising research efforts have advanced the understanding and recognition of the pathobiology of pulmonary hypertension. Despite remarkable achievements in terms of improving the survival rate, reducing disease progression, and enhancing quality of life, pulmonary arterial hypertension (PAH) is not completely curable. Therefore, an effective treatment strategy is still needed. Recently, many studies of the underlying molecular mechanisms and technological developments have led to new approaches and paradigms for PAH treatment. Management based on stem cells and related paracrine effects, epigenetic drugs and gene therapies has yielded prospective results for PAH treatment in preclinical research. Further trials are ongoing to optimize these important insights into clinical circumstances.
딥러닝 모델을 이용한 휴대용 무선 초음파 영상에서의 경동맥 내중막 두께 자동 분할 알고리즘 개발
최자영,김영재,유경민,장영우,정욱진,김광기,Choi, Ja-Young,Kim, Young Jae,You, Kyung Min,Jang, Albert Youngwoo,Chung, Wook-Jin,Kim, Kwang Gi 대한의용생체공학회 2021 의공학회지 Vol.42 No.3
Measuring Intima-media thickness (IMT) with ultrasound images can help early detection of coronary artery disease. As a result, numerous machine learning studies have been conducted to measure IMT. However, most of these studies require several steps of pre-treatment to extract the boundary, and some require manual intervention, so they are not suitable for on-site treatment in urgent situations. in this paper, we propose to use deep learning networks U-Net, Attention U-Net, and Pretrained U-Net to automatically segment the intima-media complex. This study also applied the HE, HS, and CLAHE preprocessing technique to wireless portable ultrasound diagnostic device images. As a result, The average dice coefficient of HE applied Models is 71% and CLAHE applied Models is 70%, while the HS applied Models have improved as 72% dice coefficient. Among them, Pretrained U-Net showed the highest performance with an average of 74%. When comparing this with the mean value of IMT measured by Conventional wired ultrasound equipment, the highest correlation coefficient value was shown in the HS applied pretrained U-Net.